Diagnosis and Management of Legg-Calvé-Perthes Disease in the Obese Pediatric Population
Related Experiment Video
Updated: May 7, 2026

The Lower Body Positive Pressure Treadmill for Knee Osteoarthritis Rehabilitation
Published on: July 22, 2019
Lauren Beckish1, Madison Ging1, Maria Mosman1
1Department of Physician Assistant Studies, West Liberty University, West Liberty, WV, United States of America.
Insights
Legg-Calvé-Perthes Disease (LCPD) in children is linked to poor blood flow in the hip. Obesity worsens LCPD, causing more severe symptoms and treatment challenges.
Area of Science:
- Pediatric Orthopedics
- Metabolic Bone Disease
Background:
- Legg-Calvé-Perthes Disease (LCPD) involves disrupted blood flow to the pediatric femoral head, causing avascular necrosis.
- The condition often affects children under 15, leading to bone weakening and deformity.
Purpose of the Study:
- To investigate the significant impact of obesity on Legg-Calvé-Perthes Disease (LCPD) progression.
- To understand how obesity influences LCPD diagnosis, severity, and treatment.
Main Methods:
- Review of existing literature on LCPD and obesity.
- Analysis of correlations between body mass index and LCPD outcomes.
- Examination of hormonal and inflammatory factors in obese LCPD patients.
Main Results:
- Obesity is associated with delayed LCPD diagnosis and increased disease severity.
- Obese children with LCPD show a higher incidence of bilateral involvement.
- Altered leptin, growth hormone, and inflammatory mediators are implicated in obese patients.
Conclusions:
- Obesity presents unique challenges in managing pediatric LCPD.
- Tailored treatment strategies are essential for obese children with LCPD for better outcomes.
Abstract:
Legg-Calvé-Perthes Disease (LCPD) is a condition marked by temporary blood flow disruption to the proximal femur, commonly afflicting children aged 15 and younger. The etiology of the disease is often idiopathic and involves the development of avascular necrosis of the femoral head, subsequently leading to bone weakening and deformity. Obesity exacerbates LCPD, correlating with delayed diagnosis, increased disease severity, and bilateral involvement. Leptin, growth hormone, and other inflammatory mediator alterations in obese individuals contribute to the pathogenesis. Treatment ranges from conservative measures to surgery, with particular challenges in obese patients. An improved understanding of the impact of obesity on LCPD progression is crucial for tailored management and optimal outcomes.
Related Concept Videos
Mitral Valve Prolapse II: Assessment and Management
Peripheral Artery Disease V: Postoperative Nursing Management

